Cargando…
Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
BACKGROUND: Scalp hair loss (alopecia) in women is a common ageing and senescing condition. It usually presents as androgenetic alopecia (AGA) or telogen effluvium (TE) and often has pronounced psychological consequences. ALRV5XR is a novel treatment aiming to regenerate a normal hair phenotype by t...
Autores principales: | Feldman, Peter R, Fiebig, Klaus M, Piwko, Charles, Mints, Boris M, Brown, Dennis, Cahan, Deborah J, Guevara-Aguirre, Jaime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249777/ https://www.ncbi.nlm.nih.gov/pubmed/34235415 http://dx.doi.org/10.1016/j.eclinm.2021.100978 |
Ejemplares similares
-
Sex differences in clinical trials of ALRV5XR treatment of androgenetic alopecia and telogen effluvium
por: Feldman, Peter R., et al.
Publicado: (2022) -
Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
por: Feldman, Peter R, et al.
Publicado: (2021) -
Clinical and histological challenge in the differential diagnosis of
diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata
- Part II()
por: Werner, Betina, et al.
Publicado: (2012) -
The Effectiveness and Tolerability of Preformed Growth Factors Vehiculated Through Iontophoresis on Patients with Androgenetic Alopecia and Telogen Effluvium: A Clinical Study
por: Alessandrini, Aurora Maria, et al.
Publicado: (2021) -
Anagenes statt telogenes Effluvium?
por: Gisy, Jenny
Publicado: (2022)